Latest news ...

Some of our recent news articles.

 
01
July
2019
01st July 2019
 

Venn Life Sciences to pursue ‘build to sell’ plan after merger

Combined group to fall under Open Orphan name

 
Read the full story »
 
 
12
December
2018
12th December 2018
 

Strategic Collaboration Agreement with Open Orphan DAC and Financing

 Venn Life Sciences (“Venn”) an Integrated Drug Development Partner offering a combination of drug development expertise and clinical trial design and management to pharmaceutical, biotechnology and medical device organisations announces a strategic collaboration with Open Orphan DAC and the issue of £1m in privately-held loan notes to fund an increased focus of the business into the high growth area of orphan diseases.

 
Read the full story »
 
 
28
September
2018
28th September 2018
 

Venn shares hit new low as sales slide 15%

Clinical trials group falls to a loss but is optimistic for the future
 
Read the full story »
 
 
05
July
2018
05th July 2018
 

Venn Life Sciences raises £650,000 in share sale

Proceeds to be used for the acquisition by Venn Germany of CRM Biometrics
 
Read the full story »
 
 
28
February
2018
28th February 2018
 

Venn Life Sciences reports rise in earnings despite fall in revenue

Irish drug development group targeting ‘higher value customer markets’
 
Read the full story »
 
 
27
July
2017
27th July 2017
 

Revenue continues to rise at Venn Life Sciences

New financial year ‘started well’ with contract wins of €5.7m for clinical trials group
 
Read the full story »
 
 
18
April
2017
18th April 2017
 

Irish firm hopes to catch the eyes of beauty giants

Integumen’s price has slid since flotation on the London Stock Exchange junior market
 
Read the full story »
 
 
30
March
2017
30th March 2017
 

Dublin-based Venn Life Sciences records 57% rise in 2016 income

Firm says it secured €5.7 million worth of contract deals in first two months of 2017
 
Read the full story »
 
 
09
November
2016
09th November 2016
 

Venn Life Sciences wins €2.5m clinical trials contract

Company to carry out phase III study on behalf of Swedish firm Sedana Medical
 
Read the full story »
 
 
11
May
2016
11th May 2016
 

Sales surge at clinical trials group Venn Life Sciences

Company reports maiden Ebitda profit before exceptionals on strong sales and Kinesis acquisition
 
Read the full story »
 
 
12
January
2016
12th January 2016
 

Venn Life Sciences signs contracts worth over €3.4m

Contracts with US biotech firm are extensions of an existing Phase II programme
 
Read the full story »
 
 
24
September
2015
24th September 2015
 

Venn Life Sciences to acquire Kinesis Pharma for €6.5m

Dublin-based clinical research group Venn Life Sciences is to acquire Kinesis Pharma for a total consideration of up to €6.5 million.
The company aims to raise £3.75 million through a placing of shares, to part fund the acquisition of Netherlands-based Kinesis Pharma.
 
Read the full story »
 
 
22
May
2015
22nd May 2015
 

Venn Life Sciences reports huge jump in revenues AIM-listed Irish company says revenues rose by 140% last year

Clinical research group Venn Life Sciences has reported revenue of €4.9 million for 2014, up 140 per cent on the €2.04 million announced a year earlier.
The AIM-listed Irish company also said it had revenues of €2 million booked for the first quarter of 2015.
Venn, which provides clinical trial management to pharmaceutical, biotech and medical device companies, announced a group loss of the year of €1.8 million, unchanged from a year earlier.
 
Read the full story »
 
 
26
February
2014
26th February 2014
 

Acquisition of the trading assets of Evocutis PLC

Venn Life Sciences announces the acquisition of the intellectual property rights in Labskin™, SYN1113 and related equipment of Evocutis plc, for £210,000 in new ordinary shares in Venn.
 
Read the full story »
 
 
 
 
 
 
 
 
 

About Us

SURIMS is the new name for Actex Pharma Services which was a consultancy established in 2003, supporting companies in the identification, qualification and management of quality vendors and suppliers in ingredients and formulations.

The Pharmaceutical Services Directory supports the identification and on-boarding of quality suppliers and also incorporates software features that manage relationships between suppliers and their customers. These include the building and deployment of questionnaires and assessments, electronic signatures and sign-offs and project management between vendor/partner and customer.

Access to the features and software is available on a 'pay as you go' basis, or a customised version can be licensed for your company for its own supplier on-boarding and supplier management activities. Further information on our software services please contact Tel: +353 87 294 0436 or email info@pharmaservicesdirectory.com

 
 
 

Get in Touch

The Pharmaceutical Services Directory
info@pharmaservicesdirectory.com.

 
 

© 2019 Actex Pharma Services | All Rights Reserved.